Vaccines Market Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type (Conjugated Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vacci

The vaccines market size is expected to grow from US$ 80.45 billion in 2024 to US$ 118.94 billion by 2031; it is projected to register a CAGR of 5.7% during 2025-2031. The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives are noteworthy factors contributing to the expansion of the vaccines market size. However, the high vaccine development cost and increased time to market hinder the vaccines market growth.

Artificial intelligence (AI) and machine learning are reshaping the landscape of vaccine research and development by introducing innovative methodologies that enhance speed and accuracy. One of the most critical applications of AI is in the analysis of complex genomic and immunological data. This technology enables researchers to rapidly identify potential vaccine targets by sifting through vast amounts of data—a process that would have traditionally taken years to accomplish. The ability to predict immune responses to these targets is particularly revolutionary, providing insights to design vaccines in a much shorter timeframe.

The strategic value of AI was evident during the COVID-19 pandemic, where it played a critical role in accelerating mRNA vaccine development clinical trials timelines, enabling companies to move from viral genome sequencing to regulatory approval within a year. In 2021, Pfizer leveraged an advanced AI-driven platform, SDQ, to streamline clinical data processing. This machine learning tool reduced the time required to clean and analyze trial data from over 30 days to just 22 hours after reaching efficacy milestones, significantly enhancing operational efficiency and speed to market.

In the manufacturing arena, the implementation of AI significantly enhances production efficiency. AI systems can streamline various stages of the production process, enhance quality control by monitoring and identifying deviations from expected standards, and forecast potential bottlenecks that could delay vaccine delivery. This proactive approach not only speeds up the production timeline but also ensures that vaccines are manufactured with a higher degree of reliability. In March 2025, Los Alamos announced that the scientists in Los Alamos National Laboratory are combining experimental data and AI for accelerating vaccine and drug development. The RAPTER vaccine development project is leveraging AI and experimental studies to expedite traditional research methods. It aims to create a predictive tool that analyzes pathogen genetic sequences and identifies effective vaccine options for rapid outbreak responses. The team is developing this tool using AI-based knowledge extraction, mechanistic modeling, and in vitro and in vivo experiments to test promising candidates. Initially, RAPTER will focus on three pathogens: SARS-CoV-2, Ebola virus, and Burkholderia pseudomallei, the bacterium that causes melioidosis, deemed a significant biological threat.

Overall, the integration of AI and machine learning into vaccine development processes is making this critical field more efficient, scalable, and adaptable to the rapidly evolving landscape of global health threats, ultimately contributing to more effective public health responses. This is expected to contribute to the growth of the vaccines market in the coming years.

Age Group -Based Insights

Based on age group, the vaccines market is segmented into pediatric and adult. The pediatric segment held the largest vaccines market share in 2024. Pediatric vaccines are immunizations given during infancy and childhood to protect against infectious diseases that pose significant risks in early life. These vaccines are typically scheduled in national immunization programs and include protection against diseases such as diphtheria, pertussis, tetanus (DTP), polio, rotavirus, measles, mumps, rubella (MMR), hepatitis B, pneumococcal, and more. This segment continues to grow due to rising awareness about early childhood immunity, increased global coverage efforts by organizations, and strong government mandates in both developed and developing countries. The burden of vaccine-preventable diseases in infants and the long-term health and economic benefits of early immunization have led to sustained policy and funding support. Combination vaccines that reduce the number of injections (e.g., pentavalent or hexavalent) and newer additions like HPV and malaria vaccines for children have further expanded the pediatric portfolio. Advances in vaccine technology, such as thermostable and needle-free delivery systems, also support outreach in low-resource areas, thereby fueling the vaccines market growth.

The World Health Organization and UNICEF are among the primary and secondary sources referred to while preparing the vaccines market report.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global vaccines market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.